Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Pugh

Clinical Cardiac Electrophysiology Chula Vista, CA Doctor of Osteopathy

NPI 1306077870 CMS profile 627334

765 Medical Center Ct Ste 205, Chula Vista, CA 91911

Open in the dashboard

General payments

$32,674

815 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$4,189 paid to institutions, not to them · program year 2019

Through program year 2025, Matthew Pugh of Chula Vista, CA is reported in the CMS Open Payments database as having received $32,674 across 815 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $4,189 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 65th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,772 124
2024 General $11,745 102
2023 General $3,894 123
2022 General $2,593 116
2021 General $2,710 145
2020 General $1,698 108
2019 General $2,263 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Pugh
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Matthew Pugh were reported at $7,772. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Matthew Pugh Clinical Cardiac Electrophysiology median Middle half National median
2019 $2,263 $2,361 $585–$8,260 $163
2020 $1,698 $993 $247–$4,351 $114
2021 $2,710 $1,185 $326–$4,739 $132
2022 $2,593 $2,073 $554–$6,789 $149
2023 $3,894 $2,568 $759–$8,159 $160
2024 $11,745 $2,557 $703–$7,403 $164
2025 $7,772 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $10,125 8 payments
  2. Biosense Webster, Inc. $5,400 185 payments
  3. Boston Scientific Corporation $3,725 161 payments
  4. Abbott Laboratories $3,272 104 payments
  5. Medtronic, Inc. $3,237 38 payments
  6. Biotronik Inc. $2,123 87 payments
  7. Pfizer Inc. $862 60 payments
  8. Merck Sharp & Dohme Corporation $553 22 payments
  9. CVRx, Inc. $518 15 payments
  10. Sanofi-Aventis U.S. LLC $337 16 payments
  11. Other $2,524 119 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,042 773 payments
  2. Consulting Fee $12,375 10 payments
  3. Travel and Lodging $4,011 16 payments
  4. Education $247 16 payments
Products named General payments · program years 2019–2025
  1. Carto 3 $14,115 118 payments
  2. EVERA MRI XT DR SURESCAN $2,482 8 payments
  3. WATCHMAN $1,057 40 payments
  4. ELIQUIS $838 59 payments
  5. BioMonitor Cardiology/Vascular Diseases $830 25 payments
  6. AVEIR Structural Heart $674 12 payments
  7. BIOMONITOR Cardiology/Vascular Diseases $641 27 payments
  8. VERQUVO $636 25 payments
  9. Carto 3 System $606 35 payments
  10. AVEIR Cardiac Rhythm Management $559 3 payments
  11. Other $12,098 532 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,453

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$510,612

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

45.8%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 265 $265,399
Multaq Dronedarone Hcl Brand 53 $87,448
Entresto Sacubitril/Valsartan Brand 55 $72,075
Xarelto Rivaroxaban Brand 34 $42,823
Jardiance Empagliflozin Brand 24 $26,114
Colchicine Generic 70 $2,410
Flecainide Acetate Generic 58 $2,341
Sotalol Sotalol Hcl Brand 66 $1,924
Metoprolol Succinate Generic 96 $1,379
Clopidogrel Clopidogrel Bisulfate Brand 131 $1,258

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$369,635

Medicare's payments for the services billed

Medicare patients

469

Average age 77

Services billed

2,160

205 women, 264 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Heart failure 59%
Ischemic heart disease 57%
Diabetes 54%
Arthritis 49%
Chronic kidney disease 36%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $97
$97 53 —
VERQUVO
  • Merck Sharp & Dohme Corporation $83
$83 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $37
  • PFIZER INC. $28
$64 265 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $32
$32 — —
Sotalol Hydrochloride
  • AltaThera Pharmaceuticals LLC $25
$25 66 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

815 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record